Thromb Haemost 2009; 101(04): 770-772
DOI: 10.1160/TH08-11-0777
Case Report
Schattauer GmbH

Hypodysfibrinogenemia causing mild bleeding and thrombotic complications in a compound heterozygote of AαIVS4+1G>T mutation and Aα4841delC truncation (AαPerth)

Asier Jayo
1   Department of Cellular and Molecular Physiopathology. Centro de Investigaciones Biológicas (CIB-CSIC), Madrid, Spain
,
Erin Arnold
2   Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
,
Consuelo González-Manchón
1   Department of Cellular and Molecular Physiopathology. Centro de Investigaciones Biológicas (CIB-CSIC), Madrid, Spain
,
David Green
3   Division of Hematology & Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
,
Susan T. Lord
2   Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 02. Dezember 2008

Accepted after minor revision: 28. Januar 2009

Publikationsdatum:
23. November 2017 (online)

 

 
  • References

  • 1 Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3: 1894-1904.
  • 2 Hayes T. Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med 2002; 126: 1387-1390.
  • 3 Sirridge M, Shannon R. Modified Clauss method. In: Laboratory Evaluation of Hemostasis and Thrombosis. 3rd ed. Lea & Febiger, Philadelphia, PA, USA; 1983; pp: 164-165.
  • 4 Asselta R, Duga S, Tenchini ML. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 2006; 4: 2115-2129.
  • 5 Attanasio C, de Moerloose P, Antonarakis SE. et al. Activation of multiple cryptic donor splice sites by the common congenital afibrinogenemia mutation, FGA IVS4 + 1 G-->T. Blood 2001; 97: 1879-1881.
  • 6 Homer VM, Mullin JL, Brennan SO. et al. Novel Aalpha chain truncation (fibrinogen Perth) resulting in low expression and impaired fibrinogen polymerization. J Thromb Haemost 2003; 1: 1245-1250.
  • 7 Standeven KF, Grant PJ, Carter AM. et al. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003; 107: 2326-2330.
  • 8 Rasmussen-Torvik LJ, Cushman M, Tsai MY. et al. The association of alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism in the LITE study. Thromb Res 2007; 121: 1-7.
  • 9 Ridgway HJ, Brennan SO, Faed JM. et al. Fibrinogen Otago: a major alpha chain truncation associated with severe hypofibrinogenaemia and recurrent miscarriage. Br J Haematol 1997; 98: 632-639.
  • 10 Ridgway HJ, Brennan SO, Gibbons S. et al. Fibrinogen Lincoln: a new truncated alpha chain variant with delayed clotting. Br J Haematol 1996; 93: 177-184.
  • 11 Brennan SO, Mosesson MW, Lowen R. et al. Dysfibrinogenemia (fibrinogen Wilmington) due to a novel Aalpha chain truncation causing decreased plasma expression and impaired fibrin polymerisation. Thromb Haemost 2006; 96: 88-89.
  • 12 Koopman J, Haverkate F, Grimbergen J. et al. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids A alpha 461–610 (Lys 461 AAA-->stop TAA). Blood 1992; 80: 1972-1979.
  • 13 Lefebvre P, Velasco PT, Dear A. et al. Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AalphaIVS4 + 1G>T mutation and an AalphaGln328 truncation (fibrinogen Keokuk). Blood 2004; 103: 2571-2576.